News
![Leiste32](/uploads/tableTool/UllCmsPage/image/leiste32.png)
Welcome to the homepage of AIHTA!
AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Announcement
Horizon Scanning in Onkology - Reports
We are pleased to introduce our new HSO report.
DSD HSO No. 43
Nab-Paclitaxel (Abraxane®) as first-line therapy for metastatic adenocarcinoma of the pancreas
Announcement
Treatment by clinical psychologists: Literature overview on training, methods of treatment and areas of application
In Austria, the ASVG (General Law on Social Security) currently includes clinical-psychological diagnostics, but not treatment by clinical psychologists. The LBI-HTA compiled a literature overview on “treatment by clinical psychologists” on behalf of the Austrian Federal Ministry of Health: Part I includes a comparison of training requirements of clinical psychologists in several countries and analyses Austrian stakeholder views systematically, part II presents a literature overview on treatment methods and indication areas in the international scientific literature.
Publication: LBI-HTA Project report No. 69a: https://eprints.aihta.at/1018
Contact: Nikolaus Patera
Publication: LBI-HTA Project report No. 69b: https://eprints.aihta.at/1019
Contact: Inanna Reinsperger
Announcement
Hadron Therapy: Proton and carbon ion therapy - a review on clinical evidence of efficacy, ongoing research and reimbursement
Currently, there are about 40 facilities operating worldwide (14 in Europe) that offer hadron therapy. An additional 25 facilities (9 in Europe) are under construction and will go into operation in the coming years. In 2015, the Austrian center, MedAustron, will be opened in Wiener Neustadt. In the next 3–5 years, the capacity in Europe will approximately double. Since a supply-induced demand is to be assumed due to the considerable expansion of capacity in Europe the health policy issues – underlying this report - are: for which indications (tumor entities, stages) is evidence for a better efficacy, resp., fewer side effects through hadron therapy (proton or carbon ion therapy) already available, which clinical trials are currently running, which indications are also mentioned in guidelines, and which indications are reimbursed in other social health insurance countries.
Publication: LBI-HTA Project report No. 72: https://eprints.aihta.at/1021
Contact: Claudia Wild